- Home
- PRPH vs IMRN Comparison
PRPH vs IMRN Comparison
Compare PRPH & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRPH
- IMRN
- Stock Information
- Founded
- PRPH 1989
- IMRN 1994
- Country
- PRPH United States
- IMRN Australia
- Employees
- PRPH N/A
- IMRN N/A
- Industry
- PRPH Biotechnology: Pharmaceutical Preparations
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- PRPH Health Care
- IMRN Health Care
- Exchange
- PRPH Nasdaq
- IMRN Nasdaq
- Market Cap
- PRPH 14.3M
- IMRN 15.0M
- IPO Year
- PRPH 1997
- IMRN N/A
- Fundamental
- Price
- PRPH $0.60
- IMRN $2.15
- Analyst Decision
- PRPH Strong Buy
- IMRN Strong Buy
- Analyst Count
- PRPH 1
- IMRN 1
- Target Price
- PRPH $11.00
- IMRN $5.00
- AVG Volume (30 Days)
- PRPH 321.2K
- IMRN 21.6K
- Earning Date
- PRPH 03-14-2025
- IMRN 02-26-2025
- Dividend Yield
- PRPH N/A
- IMRN N/A
- EPS Growth
- PRPH N/A
- IMRN N/A
- EPS
- PRPH N/A
- IMRN N/A
- Revenue
- PRPH $12,753,000.00
- IMRN $3,271,194.00
- Revenue This Year
- PRPH $36.93
- IMRN N/A
- Revenue Next Year
- PRPH $132.05
- IMRN N/A
- P/E Ratio
- PRPH N/A
- IMRN N/A
- Revenue Growth
- PRPH N/A
- IMRN 171.67
- 52 Week Low
- PRPH $0.56
- IMRN $1.59
- 52 Week High
- PRPH $7.48
- IMRN $5.96
- Technical
- Relative Strength Index (RSI)
- PRPH 37.26
- IMRN 56.18
- Support Level
- PRPH $0.58
- IMRN $1.85
- Resistance Level
- PRPH $0.93
- IMRN $2.20
- Average True Range (ATR)
- PRPH 0.10
- IMRN 0.22
- MACD
- PRPH 0.01
- IMRN 0.01
- Stochastic Oscillator
- PRPH 9.54
- IMRN 57.47
About PRPH ProPhase Labs Inc. (DE)
ProPhase Labs Inc is a diversified company that offers a range of services including diagnostic testing, genomics testing and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers and government organizations. The Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provide personal genomics products and services.
About IMRN Immuron Limited
Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.